Drug developer Tanox ( TNOX) said its shareholders approved its acquisition by biotech giant Genentech ( DNA).

Under the terms of the deal, Tanox stockholders will receive $20 a share in cash for each of their shares.

The decision was made by a majority vote at a special meeting of stockholders Monday. About 34.2 million shares were voted in favor of the merger, representing roughly 75.5% of Tanox's total shares and 99.9% of the shares voted at the meeting.

The transaction should close in the first quarter of this year, subject to customary closing conditions.

Shares of Tanox closed 4 cents higher at $19.81 Friday.

If you liked this article you might like

Nationwide Egg Recall Expanded

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective

Heavy Weights: More Expensive, Less Effective